

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berrī Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542

Date: 11th February, 2021

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400001
Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)

Sub: Submission of Outcomes of Board Meeting and Un-Audited Financial Results for the quarter and nine months ended 31st December, 2020

1. Intimation and disclosure under Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Un-Audited Financial Results and Limited Review Report for the quarter and nine months ended 31.12.2020
2. Appointment of Rohit Batham & Associates, Practicing Company Secretaries, with immediate effect to issue Annual Secretarial Compliance Report for the Financial Year 2020-21 as per the Regulation 24A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015 read with Circular No. CIR/CFD/CMD1/27/2019 dated February 08, 2019 issued by Securities and Exchange Board of India and other applicable provisions thereto
3. Appointment of Andros & Co., Chartered Accountants, with immediate effect to issue Reconciliation of Share Capital Audit Report on quarterly basis for the Financial Year 2021-22 as per the Regulation 76 of SEBI (Depositories and Participants) Regulations, 1996 and any other provision applicable thereto

Dear Sir/ Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ("Company") in its meeting held today approved the Un-Audited Financial Results (Standalone) for the Quarter and Nine Months ended 31st December, 2020 of the Company as per Indian Accounting Standards (IND-AS) along with the Limited Review Report. Copy of the results along with the Limited Review Report of Statutory Auditors is attached herewith for your perusal.

Further due to the applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Companies Act, 2013, following approvals has been accorded in Board Meeting held today:

1. Appointment of Rohit Batham & Associates, Practicing Company Secretaries, with immediate effect to issue Annual Secretarial Compliance Report for the Financial Year 2020-21 as per the Regulation 24A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015 read with Circular No. CIR/CFD/CMD1/27/2019 dated February 08, 2019 issued by Securities and Exchange Board of India and other applicable provisions thereto
2. Appointment of Andros & Co., Chartered Accountants, with immediate effect to issue Reconciliation of Share Capital Audit Report on quarterly basis for the Financial Year 2021-22 as per the Regulation 76 of SEBI (Depositories and Participants) Regulations, 1996 and any other provision applicable thereto

The above information will also be available on the Company's Website, www.genomicvalley.com.



The meeting of the Board of Directors commenced on 11:45 A.M. and concluded at 02:50 P.M.

Please take the above on records.

Thanking you.

Yours sincerely

For Genomic Valley Biotech Limited

Yogesh Agrawal
Managing Director
DIN: 01165288
Add: G-74, Pushkar Enclave,
Paschim Vihar Delhi - 110063

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029

Genomic Valley Biotech Limited today reported its financial performance
for the quarter and nine months ended 31/12/2020

Statement of Standalone Un-Audited Financial Results as compared to the previous quarter and year are:

In Rs.

Sr. No.	Particular	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for previous period ended	Previous year ended
		31-Dec-20	30-Sep-20	31-Dec-19	31-Dec-20	31-Dec-19	31-Mar-20
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I	Revenue From Operations	916,620	669,690	1,800,000	1,863,910	5,493,129	8,465,629
II	Other Income	-	-	91,371	-	217,040	140,869
III	Total Revenue (I+II)	916,620	669,690	1,891,371	1,863,910	5,710,169	8,606,499
IV	Expenses						
	Cost of materials consumed	24,602	8540	-	33,142	16,265	88,265
	Purchases of Stock-in-Trade	-	-	-	-	-	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	765,600	-	-765,600
	Employee benefits expense	181,500	194,444	252,667	701,434	1,540,426	1,765,260
	Financial costs	-	-	-	-	-	1,798,878
	Depreciation and amortization expense	481,439	481,439	473,378	1,444,317	1,280,179	1,785,803
	Other expenses	365,342	248,963	238,057	674,184	1,613,114	1,876,582
	Total Expenses (IV)	1,052,883	933,386	964,102	3,618,677	4,449,985	6,549,189
V	Profit / (Loss) before exceptional item and tax (III-IV)	-136,263	-263,696	927,269	-1,754,767	1,260,185	2,057,310
VI	Exceptional Item	-	-	-	-	-	-
VII	Profit/loss before Tax (V-VI)	-136,263	-263,696	927,269	-1,754,767	1,260,185	2,057,310
VIII	Tax expenses						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-	-	-	-	-	-802,616
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	-136,263	-263,696	927,269	-1,754,767	1,260,185	2,859,926
X	Profit/ (Loss) from discontinued operations	-	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-	-
XII	Profit/ (Loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit/Loss for the period (IX+XII)	-136,263	-263,696	927,269	-1,754,767	1,260,185	2,859,926
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	-136,263	-263,696	927,269	-1,754,767	1,260,185	2,859,926
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	3,054,500	3,054,500	3,054,500	3,054,500	3,054,500	3,054,500
XVII	Earning Per Equity Share (for continuing operation):						
	1) Basic	-0.04	-0.09	0.30	-0.57	0.41	0.94
	2) Diluted	-0.04	-0.09	0.30	-0.57	0.41	0.94
XVIII	Earning Per Equity Share (for discontinued operation):						
	1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):						
	1) Basic	-0.04	-0.09	0.30	-0.57	0.41	0.94
	2) Diluted	-0.04	-0.09	0.30	-0.57	0.41	0.94



Notes :

- 1 The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on 11/02/2021. The Statutory Auditors of the company have carried out a Limited Review of the Financial Results for these financials.

- 2 The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.

- 3 Company's Business activity falls within a single business segment i.e. Horticulture in terms of Ind-AS 108 on Segment Reporting.

- 4 Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.

For and on behalf of the Board of Genomic Valley Biotech Limited


Rajesh Agrawal
(Managing Director)

DIN-01165288

Add: G-74 Pushkar Enclave
Paschim Vihar, New Delhi-110063

Place : Delhi

Dated : 11.02.2021

LIMITED REVIEW REPORT

To,
The Board of Directors of
Genomic Valley Biotech Limited,
4 K.M. Stone, Berri Chharra Road,
Village- Kherka Musalman, P.O. Tandaheeri,
Tehsil-Bahadurgarh, District-Jhajjar, Haryana-124507.


Subject: Limited Review Report on the Un-Audited Financial Results for the Quarter and nine months ended on 31st December, 2020

We have reviewed the accompanying statement of unaudited financial results for the quarter and nine months ended December 31, 2020 ('the statement') of Genomic Valley Biotech Limited ('the Company') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For ANDROS & CO.
Chartered Accountants

Bhavuk Garg

(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)

Place: Delhi
Date: 11.02.2021

UDIN: 21502310 AAAAEP2902